m6A-centered Drug Response Information

General Information of the Drug (ID: M6ADRUG0101)
Name
Cetuximab
Status Approved [1]
TTD Drug ID
D0N5OV
DrugBank ID
DB00002
Full List of m6A Targets Related to This Drug
Transcription factor 7-like 2 (TCF7L2)
 Target Info 
In total 1 item(s) under this target gene
Experiment 1 Reporting the m6A-centered Drug Response by This Target Gene [2]
Response Summary MIR100HG and hnRNPA2B1 interact to control the transcriptional activity of Wnt signaling in CRC via regulation of Transcription factor 7-like 2 (TCF7L2) mRNA stability. These findings identified MIR100HG as a potent EMT inducer in CRC that contribute to cetuximab resistance and metastasis by activation of a MIR100HG/hnRNPA2B1/TCF7L2 feedback loop.
Responsed Disease Colorectal cancer ICD-11: 2B91
 Disease Info 
Target Regulator Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) READER
 Regulator Info 
Target Regulation Up regulation
Pathway Response Wnt signaling pathway hsa04310
Cell Process Epithelial-mesenchymal transition
In-vitro Model VACO 9P Rectal adenocarcinoma Homo sapiens CVCL_5413
T84 Colon adenocarcinoma Homo sapiens CVCL_0555
SW948 Colon adenocarcinoma Homo sapiens CVCL_0632
SW837 Rectal adenocarcinoma Homo sapiens CVCL_1729
SW620 Colon adenocarcinoma Homo sapiens CVCL_0547
SW480 Colon adenocarcinoma Homo sapiens CVCL_0546
SW48 Colon adenocarcinoma Homo sapiens CVCL_1724
SW403 Colon adenocarcinoma Homo sapiens CVCL_0545
SW1116 Colon adenocarcinoma Homo sapiens CVCL_0544
SK-CO-1 Colon adenocarcinoma Homo sapiens CVCL_0626
RKO Colon carcinoma Homo sapiens CVCL_0504
NCI-H716 Cecum adenocarcinoma Homo sapiens CVCL_1581
NCI-H508 Cecum adenocarcinoma Homo sapiens CVCL_1564
LS174T Colon adenocarcinoma Homo sapiens CVCL_1384
LS123 Colon adenocarcinoma Homo sapiens CVCL_1383
LoVo Colon adenocarcinoma Homo sapiens CVCL_0399
LIM2405 Cecum adenocarcinoma Homo sapiens CVCL_4437
LIM1215 Colon adenocarcinoma Homo sapiens CVCL_2574
HuTu 80 Duodenal adenocarcinoma Homo sapiens CVCL_1301
HT29 Colon cancer Mus musculus CVCL_A8EZ
HCT 8 Colon adenocarcinoma Homo sapiens CVCL_2478
HCT 15 Colon adenocarcinoma Homo sapiens CVCL_0292
HCT 116 Colon carcinoma Homo sapiens CVCL_0291
GEO Colon carcinoma Homo sapiens CVCL_0271
DLD-1 Colon adenocarcinoma Homo sapiens CVCL_0248
DiFi Colorectal carcinoma Homo sapiens CVCL_6895
COLO 320DM Colon adenocarcinoma Homo sapiens CVCL_0219
COLO 205 Colon adenocarcinoma Homo sapiens CVCL_0218
Caco-2 Colon adenocarcinoma Homo sapiens CVCL_0025
In-vivo Model Established subcutaneous xenografts in athymic nude mice with MIR100HGKOE4 CC-CR cells transduced with a luciferase-expressing lentiviral vector and then treated the mice with cetuximab.
Mir-100-let-7a-2-mir-125b-1 cluster host gene (MIR100HG)
 Target Info 
In total 1 item(s) under this target gene
Experiment 1 Reporting the m6A-centered Drug Response by This Target Gene [2]
Response Summary Mir-100-let-7a-2-mir-125b-1 cluster host gene (MIR100HG) and hnRNPA2B1 interact to control the transcriptional activity of Wnt signaling in CRC via regulation of TCF7L2 mRNA stability. These findings identified MIR100HG as a potent EMT inducer in CRC that will contribute to cetuximab resistance and metastasis by activation of a MIR100HG/hnRNPA2B1/TCF7L2 feedback loop.
Responsed Disease Colorectal cancer ICD-11: 2B91
 Disease Info 
Target Regulator Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) READER
 Regulator Info 
Target Regulation Up regulation
Pathway Response Wnt signaling pathway hsa04310
Cell Process Epithelial-mesenchymal transition
In-vitro Model VACO 9P Rectal adenocarcinoma Homo sapiens CVCL_5413
T84 Colon adenocarcinoma Homo sapiens CVCL_0555
SW948 Colon adenocarcinoma Homo sapiens CVCL_0632
SW837 Rectal adenocarcinoma Homo sapiens CVCL_1729
SW620 Colon adenocarcinoma Homo sapiens CVCL_0547
SW480 Colon adenocarcinoma Homo sapiens CVCL_0546
SW48 Colon adenocarcinoma Homo sapiens CVCL_1724
SW403 Colon adenocarcinoma Homo sapiens CVCL_0545
SW1116 Colon adenocarcinoma Homo sapiens CVCL_0544
SK-CO-1 Colon adenocarcinoma Homo sapiens CVCL_0626
RKO Colon carcinoma Homo sapiens CVCL_0504
NCI-H716 Cecum adenocarcinoma Homo sapiens CVCL_1581
NCI-H508 Cecum adenocarcinoma Homo sapiens CVCL_1564
LS174T Colon adenocarcinoma Homo sapiens CVCL_1384
LS123 Colon adenocarcinoma Homo sapiens CVCL_1383
LoVo Colon adenocarcinoma Homo sapiens CVCL_0399
LIM2405 Cecum adenocarcinoma Homo sapiens CVCL_4437
LIM1215 Colon adenocarcinoma Homo sapiens CVCL_2574
HuTu 80 Duodenal adenocarcinoma Homo sapiens CVCL_1301
HT29 Colon cancer Mus musculus CVCL_A8EZ
HCT 8 Colon adenocarcinoma Homo sapiens CVCL_2478
HCT 15 Colon adenocarcinoma Homo sapiens CVCL_0292
HCT 116 Colon carcinoma Homo sapiens CVCL_0291
GEO Colon carcinoma Homo sapiens CVCL_0271
DLD-1 Colon adenocarcinoma Homo sapiens CVCL_0248
DiFi Colorectal carcinoma Homo sapiens CVCL_6895
COLO 320DM Colon adenocarcinoma Homo sapiens CVCL_0219
COLO 205 Colon adenocarcinoma Homo sapiens CVCL_0218
Caco-2 Colon adenocarcinoma Homo sapiens CVCL_0025
In-vivo Model Established subcutaneous xenografts in athymic nude mice with MIR100HGKOE4 CC-CR cells transduced with a luciferase-expressing lentiviral vector and then treated the mice with cetuximab.
References
Ref 1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6882).
Ref 2 Interaction of lncRNA MIR100HG with hnRNPA2B1 facilitates m(6)A-dependent stabilization of TCF7L2 mRNA and colorectal cancer progression. Mol Cancer. 2022 Mar 12;21(1):74. doi: 10.1186/s12943-022-01555-3.